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ATP-binding cassette transporter G2 (ABCG2) is a plasma membrane protein that
regulates the pharmacokinetics of a variety of drugs and serum uric acid (SUA) levels in
humans. Despite the pharmacological and physiological importance of this transporter,
there is no clinically available drug that modulates ABCG2 function. Therefore, to
identify such drugs, we investigated the effect of drugs that affect SUA levels on
ABCG2 function. This strategy was based on the hypothesis that the changes of
SUA levels might caused by interaction with ABCG2 since it is a physiologically
important urate transporter. The results of the in vitro screening showed that 10 of 25
drugs investigated strongly inhibited the urate transport activity of ABCG2. Moreover,
febuxostat was revealed to be the most promising candidate of all the potential ABCG2
inhibitors based on its potent inhibition at clinical concentrations; the half-maximal
inhibitory concentration of febuxostat was lower than its maximum plasma unbound
concentrations reported. Indeed, our in vivo study demonstrated that orally administered
febuxostat inhibited the intestinal Abcg2 and, thereby, increased the intestinal absorption
of an ABCG2 substrate sulfasalazine in wild-type mice, but not in Abcg2 knockout mice.
These results suggest that febuxostat might inhibit human ABCG2 at a clinical dose.
Furthermore, the results of this study lead to a proposed new application of febuxostat
for enhancing the bioavailability of ABCG2 substrate drugs, named febuxostat-boosted
therapy, and also imply the potential risk of adverse effects by drug-drug interactions
that could occur between febuxostat and ABCG2 substrate drugs.
Keywords: allopurinol, BCRP, benzbromarone, bioavailability, drug-drug interactions, drug repositioning,
topiroxostat, URAT1
Abbreviations: ABC, ATP-binding cassette; ANOVA, analysis of variance; AUC, area under the blood concentration-time
curve; Cmax, maximum drug concentration; CYP, cytochrome P450; DMEM, Dulbecco’s Modified Eagle’s Medium; DPM,
disintegrations per minute; EGFP, enhanced green fluorescent protein; fu, unbound fraction; IC50, half-maximal inhibitory
concentration; KO, knockout; LC/MS/MS, liquid chromatography-tandem mass spectrometry; MDR, multidrug resistance;
PDD, photodynamic diagnosis; PDT, photodynamic therapy; SNP, single nucleotide polymorphism; SUA, serum uric acid;
TLS, tumor lysis syndrome; URAT1, urate transporter 1; WT, wild-type; XO, xanthine oxidase.
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INTRODUCTION
ATP-binding cassette transporter G2 (ABCG2) is a member
of ABC transporter superfamily and is recognized as one of
the most important drug eﬄux transporters (Giacomini et al.,
2010; Lee et al., 2015; Mao and Unadkat, 2015). Following the
identification of the expression of this protein as the cause of
acquired multidrug resistance (MDR) in breast cancer cell lines,
ABCG2 has been termed breast cancer resistance protein (Doyle
et al., 1998). ABCG2 is expressed not only in cancer tissues but
also in numerous normal tissues such as the small intestine and
kidney (Doyle et al., 1998). Accumulating evidence indicates that
ABCG2 plays a pivotal role as a gatekeeper against xenobiotics
(Jonker et al., 2002; Giacomini et al., 2010).
ABCG2 regulates the pharmacokinetics and efficacy of its
substrate drugs. In the small intestine, ABCG2 is involved in the
eﬄux of its substrates from the epithelial cells into the intestinal
lumen, which could lower their bioavailability. For instance, the
plasma concentrations (Yamasaki et al., 2008) and efficacy (Wiese
et al., 2014) of orally administered sulfasalazine, an antirheumatic
drug, are modulated by the function of ABCG2, which appears
to be affected by at least one SNP in its cognate gene ABCG2 in
humans. ABCG2 often lowers the bioavailability of other drugs
such as rosuvastatin (Keskitalo et al., 2009; Tomlinson et al.,
2010), which is widely used to treat dyslipidemia, and sunitinib
(Mizuno et al., 2010), a multi-targeted receptor tyrosine kinase
inhibitor used in cancer chemotherapy. The intestinal inhibition
of ABCG2 would be an effective strategy to improve the efficacy
of such drugs by enhancing their bioavailability. Therefore, the
clinical inhibition of ABCG2 may be beneficial, although there
are currently no appropriate drugs and candidates to inhibit
ABCG2.
Recently, we and other research groups have independently
found that ABCG2 is a physiologically important regulator of
urate (Matsuo et al., 2009; Woodward et al., 2009; Ichida et al.,
2012; Matsuo et al., 2014) as well as URAT1, a major component
of the urate reabsorption system in the kidney and a target of
hyperuricemia therapy (Enomoto et al., 2002). Hyperuricemia
is defined as SUA levels > 7.0 mg/dL (Yamanaka, 2011) and
is associated with some diseases such as metabolic syndrome,
hypertension and gout (Richette et al., 2014). Genetically,
decreased ABCG2 function is one of the major risk factors of
hyperuricemia (Matsuo et al., 2009), since ABCG2 contributes to
both intestinal and urinary excretion of urate from the human
body into the feces and urine, respectively (Ichida et al., 2012;
Matsuo et al., 2014). Thus, it is possible that increasing ABCG2
function could contribute to decreasing SUA levels in patients
with hyperuricemia.
To date, safe modulation of ABCG2 function by chemicals
in humans has not been achieved. Since both the inhibition
and enhancement of ABCG2 function could have clinical
consequences as described above, numerous efforts have been
made to investigate and develop chemical compounds that
interact with ABCG2. Historically, some promising ABCG2
inhibiting compounds, such as Ko143 (Allen et al., 2002) and
elacridar (GF120918) (Hyafil et al., 1993), have been discovered,
which were targeted at overcoming ABCG2-induced MDR.
However, the efficacy and safety of these compounds in humans
remain unclear, because, to our knowledge, their safety in humans
has not been demonstrated in clinical studies. The similar
problem is also the case for the new ABCG2 inhibitors developed
recently (Juvale and Wiese, 2015; Ricci et al., 2016). Therefore,
we aimed to identify a solution by exploring new promising
agents for ABCG2 regulation from drugs currently available on
the market. Since the approved drugs have a low risk of adverse
effects in humans, this drug repositioning approach is expected
to be highly feasible. In addition, based on the physiological
function of ABCG2 as a urate transporter, we considered that
some drugs that affect SUA levels (SUA-affecting drugs) might
potentially interact with ABCG2. In this context, we chose the
SUA-affecting drugs as a source of the screening library in this
study.
The drugs investigated in this study were selected based
on clinical reports demonstrating their SUA level altering
effects in humans. The results of the in vitro investigation
showed that 10 drugs potently inhibited ABCG2. Among them,
febuxostat, a clinically used SUA-lowering drug, exhibited the
strongest inhibitory effect on ABCG2 in vitro. We also revealed
that febuxostat could enhance the intestinal absorption of
sulfasalazine, a well-known ABCG2 substrate in both humans
(Yamasaki et al., 2008) and mice (Zaher et al., 2006), by using
WT and Abcg2 KO mice. Our findings suggest novel potential
applications and risks in clinical use of febuxostat.
MATERIALS AND METHODS
Materials
The following compounds were purchased commercially from
the sources indicated: allopurinol, benzbromarone, cyclosporine,
D-fructose, elacridar, furosemide, hydrochlorothiazide,
nicotinic acid, oxypurinol, rosuvastatin calcium salt, salicylic
acid, 4-hydroxy chalcone (Wako Fine Chemical, Osaka,
Japan); atorvastatin, chlorothiazide, febuxostat, mizoribine,
pyrazinecarboxylic acid, ribavirin, tacrolimus, xylitol (Tokyo
Chemical Industry, Tokyo, Japan); ethambutol, losartan (LKT
Laboratories, St Paul, MN, USA); fenofibrate, probenecid,
sulfasalazine, Ko143, ATP, AMP, creatine phosphate disodium
salt tetrahydrate, creatine phosphokinase type I from rabbit
muscle (Sigma-Aldrich, St. Louis, MO, USA); pyrazinamide
(ACROS ORGANICS, Geel, Belgium); theophylline (Nacalai
Tesque, Kyoto, Japan); and topiroxostat (MedChem Express,
Princeton, NJ, USA). The [8-14C]-uric acid (53 mCi/mmol) was
from American Radiolabeled Chemicals (St. Louis, MO, USA).
All other chemicals used were commercially available and of
analytical grade.
Cell Culture
Human embryonic kidney 293 cell-derived 293A cells were
purchased from Life Technologies (Carlsbad, CA, USA)
and cultured in DMEM (Nacalai Tesque) supplemented
with 10% fetal bovine serum (Biowest, Nuaillé, France), 1%
penicillin/streptomycin, 2 mM L-glutamine (Nacalai Tesque),
and 1 × Non-Essential Amino Acid (Life Technologies) at 37◦C
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in an atmosphere of 5% CO2 as described previously (Toyoda
et al., 2016a). All experiments were carried out with 293A cells
at passages 10–20. To express human ABCG2 (NM_004827)
fused with Myc-tag at its N-terminus (Myc-ABCG2) and
EGFP (control), we used Myc-ABCG2 and EGFP-expressing
adenoviruses constructed in our previous study (Ito et al., 2015),
respectively. To express the URAT1, open reading frame of
URAT1 (NM_144585.3) was cloned into a pcDNA3.1(+) vector
(Life Technologies) with a FLAG tag at its N-terminus. To
express mouse Abcg2 and EGFP (control), open reading frames
of mouse Abcg2 (NM_011920) and EGFP were inserted into a
pcDNA3.3 vector (Life Technologies), respectively.
Animals
The FVB/NJcl WT mice were purchased from CLEA Japan
(Tokyo, Japan). The Abcg2 KO mice (Ichida et al., 2012) had
been maintained in our laboratory as described previously. All the
animals were housed in temperature- and humidity-controlled
animal cages with a 12-h dark-light cycle, and free access to
water and standard animal chow (MF, Oriental Yeast Company,
Tokyo, Japan) as described previously (Ito et al., 2014; Takada
et al., 2015). In the present study, all the in vivo experiments were
conducted with 6–8-week-old male mice. The animal research
protocols used in the present study were approved by the Animal
Studies Committee of the University of Tokyo.
In vitro Urate Transport Assay With
ABCG2-Expressing Plasma Membrane
Vesicles
The membrane vesicles were prepared from 293A cells infected
with EGFP- or Myc-ABCG2- expressing adenovirus as described
previously (Hayashi et al., 2005). Similarly, mouse Abcg2-
expressing plasma membrane vesicles were prepared from 293A
cells 48 h after the plasmid transfection using Polyethylenimine
“MAX” (PEI-MAX) (1 mg/mL in milliQ water, pH 7.0;
Polysciences, Warrington, PA, USA) as described previously
(Stiburkova et al., 2016). The [8-14C]-urate transport assay
with the ABCG2/Abcg2-expressing membrane vesicles was
performed using a rapid filtration technique (Matsuo et al.,
2009; Toyoda et al., 2016b). The urate transport activity was
calculated as an incorporated clearance (µL/mg protein/min):
(incorporated level of urate [DPM/mg protein/min]/urate level
in the incubation mixture [DPM/µL]). ATP-dependent urate
transport was calculated by subtracting the urate transport
activity in the absence of ATP from that in the presence of ATP.
Calculation of the Half-Maximal
Inhibitory Concentration (IC50) Values
and the Plasma Concentrations of Each
Drug
The IC50 values of each test compound against the urate transport
by ABCG2 were calculated as follows. First, the urate transport
activities were measured in the presence of SUA-affecting drugs at
several concentrations. The transport activities were expressed as
a percentage of control (100%). Then, the calculated values were
fitted to the following formula using the least-squares methods
(Powles et al., 2007) with the Excel 2007 (Microsoft, Redmond,
WA, USA) program:
Predicted value [%] = 100− (Emax×Cn/ICn50+Cn)
where, Emax is the maximum effect, C is the drug concentration,
and n is the sigmoid-fit factor. The unbound concentrations
of each drug in human plasma were calculated based on the
general information provided by pharmaceutical industries. The
unbound fraction in human plasma (fu) was calculated by
subtracting the ratio of bound drugs from total drugs. The
maximum unbound concentration of each drug in human plasma
(fuCmax) was calculated by multiplying fu and the reported Cmax
together.
In vitro Urate Uptake Assay in
URAT1-Expressing 293A Cells
The 293A cells were seeded on a 12-well plate (Becton Dickenson
& Co., Franklin Lakes, NJ, USA) at 2 × 105 cells/well. Twenty-
four hours after seeding, the cells were transiently transfected
with the FLAG-URAT1 pcDNA3.1(+) vector or empty vector
using PEI-MAX (0.4 µg plasmid/4 µL PEI-MAX/100 µL serum
free DMEM/2 × 105 cells) as described previously (Stiburkova
et al., 2016). Forty-eight hours after the transfection, the cells were
washed twice with Buffer T2 (125 mM Na-gluconate, 4.8 mM
K-gluconate, 1.2 mM KH2PO4, 1.2 mM MgSO4, 1.3 mM Ca-
gluconate, 25 mM HEPES, 5.6 mM D-glucose, and pH 7.4) and
preincubated in Buffer T2 for 15 min at 37◦C. Then, the buffer
was exchanged to fresh Buffer T2 containing 2 µM [8-14C]-
urate, and the cells were further incubated for the indicated
periods. Subsequently, the cells were washed with ice-cold Buffer
T2 twice and then lysed with 500 µL 0.2 M NaOH on ice with
gently shaking for 1 h. The resulting lysates were transferred
to 1.5-mL tubes, neutralized with 100 µL 1 M HCl, and then
the radioactivity were measured using a liquid scintillator. The
protein concentrations were determined using a bicinchoninic
acid assay kit (Life Technologies) according to the manufacturer’s
instruction. The urate transport activity was calculated as the
incorporated clearance (µL/mg protein/min): (incorporated level
of urate [DPM/mg protein/min]/urate level in the incubation
mixture [DPM/µL]). URAT1-dependent urate transport activity
was calculated by subtracting the urate transport activity of mock
cells from that of the URAT1-expressing cells.
Western Blot Analysis
The expression of Myc-ABCG2 on membrane vesicles and
FLAG-URAT1 in transiently transfected-293A cells was
confirmed using western blot analysis. To obtain the cell
lysate samples of URAT1-expressing 293A cells, 48 h after
the transfection, the cells were washed twice with phosphate-
buffered saline without Ca2+ and Mg2+ and then dissolved in
RIPA buffer (0.1% SDS, 0.5% deoxycholate, 1% NP40, 150 mM
NaCl, 50 mM Tris-HCl, and pH 7.4) containing protease
inhibitor cOmplete, EDTA-free (Roche, Basel, Switzerland).
After centrifugation at 15,000× g for 10 min at 4◦C, the resulting
supernatants were collected as the cell lysates. The membrane
vesicles prepared from the adenovirus-infected 293A cells or
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cell lysates of vector-transfected 293A cells were subjected to
8.5% SDS-polyacrylamide gel electrophoresis and transferred
to PVDF membranes (Immobilon, Millipore Corporation,
Billerica, MA, USA). After blocking with 3% bovine serum
albumin in 0.05% Tween 20 containing Tris-buffered saline
for 1 h at room temperature, the membranes were treated
with following antibodies as described previously (Matsuo
et al., 2009); mouse anti-ABCG2 antibody (BXP-21) (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) (1:1000), a mouse
anti-FLAG M2 antibody (Sigma Aldrich) (1:1000), a rabbit
anti-Na+/K+-ATPase antibody (Santa Cruz Biotechnology)
(1:1000), anti-mouse IgG or anti-rabbit IgG antibody labeled
with horseradish peroxidase (GE Healthcare, Piscataway, NJ,
USA) (1:2500). The immunoblotted membranes were treated
with ECL Prime (GE Healthcare) and analyzed using a Chemidoc
XRS (Bio-Rad Laboratories, Richmond, CA, USA).
In vivo Abcg2 Inhibition Test
We conducted an in vivo Abcg2 inhibition test to examine the
effect of febuxostat on the intestinal absorption of sulfasalazine,
an ABCG2 substrate. Febuxostat was dissolved in 100 mM
sodium bicarbonate buffer, pH 10. Prior to the experiment,
the mice were fasted overnight, and then they were orally
administered febuxostat by gavage at a dose of 150 mg/kg body
weight (b.w.) with the expectation of complete inhibition of
intestinal Abcg2. Twenty minutes later, sulfasalazine (20 mg/kg
b.w.) was orally administered by gavage. At the indicated periods,
the mice were anesthetized with diethyl ether and blood was
collected from the jugular veins using heparinized syringes,
followed by centrifugation at 3,000× g for 10 min. The resulting
supernatant (plasma) was collected and stored at−80◦C until the
LC/MS/MS analysis was performed.
Measurement of Plasma Concentration
of Sulfasalazine Using LC/MS/MS
The collected plasma was deproteinized with a fourfold volume
of methanol containing 2 µg/mL 4-hydroxy chalcone as an
internal standard. After vortexing for 10 min, the samples
were centrifuged at 20,000 × g for 15 min at 4◦C. Then, the
supernatants were analyzed using the LC/MS/MS technique.
The LC/MS/MS analysis was conducted using an ultra-
performance LC system connected to a Xevo TQ-S mass
spectrometer (Waters Corporation, Milford, MA, USA). The
samples were separated using a 1.7-µm particle ACQUITY C18
column (2.1 mm × 100 mm, Waters), maintained at 50◦C,
under gradient mobile phase conditions with a mixture of 0.1%
formic acid in water and 0.1% formic acid in acetonitrile as
solvents (0–1 min 70:30 v/v, 1–3 min 70:30 to 2:98 v/v, 3–
5 min 2:98 v/v, and 5–6.5 min 70:30 v/v) with a flow rate of
0.3 mL/min. The separated samples were introduced into an
MS in the positive and negative electrospray ionization mode
for sulfasalazine and 4-hydroxy chalcone, respectively. Each
compound was quantified in the multiple reactions monitoring
mode (399.24 > 119.02, Cone 20 V, Collision 46 eV for
sulfasalazine; 223.15 > 117.00, Cone 50 V, and Collision 36 eV
for 4-hydroxy chalcone).
The AUC of sulfasalazine was calculated as the total area of the
trapezoids formed by the points of the concentration and time in
the concentration-time plots.
Statistical Analysis
All statistical analyses were performed using the Excel 2007
program. Significant differences were identified using a two-way
ANOVA followed by Tukey-Kramer post hoc test. The values were
considered significant when P < 0.05.
RESULTS
Effects of SUA-Affecting Drugs on the
Urate Transport Activity of ABCG2
In vitro
To examine the effects of 25 SUA-affecting drugs (Table 1) on
ABCG2 function, we measured the urate transport activity of
ABCG2 in the presence of each SUA-affecting drug. Expression
TABLE 1 | List of SUA-affecting drugs in the present study.
Effect on
SUA levels
Drugs Maximum
concentration in the
present study [µM]
References
I
Decrease
expectedly
Allopurinol 300 Watts et al., 1965
Benzbromarone 100 Enomoto et al., 2002
Febuxostat 10 Osada et al., 1993
Oxypurinol 100 Watts et al., 1965
Probenecid 100 Gutman et al., 1954
Topiroxostat 3 Okamoto et al., 2003
II
Decrease
unexpectedly
Atorvastatin∗ 30 Ogata et al., 2010
Fenofibrate 300 Harvengt et al., 1980
Losartan 300 Kamper and Nielsen,
2001
Rosuvastatin∗ 100 Ogata et al., 2010
III
Increase
unexpectedly
Chlorothiazide 300 Kelley et al., 1973
Cyclosporine∗ 30 Palestine et al., 1984
Ethambutol 1000 Postlethwaite et al.,
1972
Fructose 1000 Thomas et al., 1975
Furosemide 300 Kelley et al., 1973
Hydrochlorothiazide 1000 Healey et al., 1959
Mizoribine 300 Ishikawa et al., 1986
Nicotinic acid 300 Cruess-Callaghan and
FitzGerald, 1966
Pyrazinamide 300 Cullen et al., 1956
Pyrazinecarboxylic
acid
1000 Cullen et al., 1956
Ribavirin 1000 Yamashita et al., 2008
Salicylic acid 1000 Yu and Gutman, 1959
Tacrolimus∗ 30 Kanbay et al., 2005
Theophylline 100 Yamamoto et al., 1991
Xylitol 1000 Thomas et al., 1975
∗Reportedly interact with ABCG2.
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of ABCG2 in the plasma membrane vesicles was confirmed
using western blot analysis (Figure 1A). According to our
previous reports (Matsuo et al., 2009; Stiburkova et al., 2016),
we used 20 µM of urate in reaction mixtures in the following
experiments. First, we examined the time-dependent increase
in ATP-dependent urate transport into the ABCG2-expressing
plasma membrane vesicle (Figure 1B). The urate transport
activities of ABCG2 were higher than those of the mock
(EGFP), and linearly increased for 20 min. Therefore, we
examined the effect of SUA-affecting drugs on ABCG2 for
10 min at the indicated concentrations in Table 1. In this
experiment, the concentrations of each drug (3–1000 µM) were
determined as the maximum soluble levels in the transport
buffer.
The in vitro screening result revealed that 10 of the 25
drugs investigated decreased the urate transport activity of
ABCG2 to <20% of that of the vehicle control (Figure 1C).
Although 12 drugs tended to increase the urate transport
activity of ABCG2, their effects were slight compared to
the drastic inhibitory effects of the 10 drugs. Therefore,
we focused on the most active 10 drugs in the further
analyses.
Febuxostat, an SUA-Lowering Drug
Inhibited ABCG2 at Clinical
Concentrations In vitro
Since the in vitro screening was conducted in the presence
of maximum concentrations of each drug, we subsequently
estimated the clinical effects of the selected 10 drugs. First,
to determine the IC50 values of each drug against the urate
transport activity of ABCG2, we measured the urate transport
activities in the presence of several concentrations of each
drug (Figure 2). Then, the IC50 values were calculated from
the results obtained using the least-squares methods (Table 2).
Among the 10 drugs we examined, three (benzbromarone,
topiroxostat and febuxostat) potently inhibited ABCG2 with
IC50 values at submicromolar concentrations (0.20, 0.18, and
0.027 µM, respectively). Indeed, these values were considerably
lower than those of four drugs that have been reported to interact
with ABCG2, atorvastatin (4.3 µM), cyclosporine (3.2 µM),
tacrolimus (3.1 µM) and rosuvastatin (2.3 µM).
To further characterize the potent inhibition of ABCG2 by
febuxostat, we compared the activity of ABCG2 in the presence
of febuxostat and two well-known ABCG2 inhibitors; Ko143,
a fumitremorgin C analog, and elacridar (GF120918). In the
FIGURE 1 | Effect of serum uric acid (SUA)-affecting drugs on the urate transport activity of ABCG2. (A) Expression of ABCG2 on membrane vesicles.
Membrane vesicles (5 µg) were subjected to western blot analysis using a BXP-21, an anti-ABCG2 or anti-Na+/K+-ATPase antibody. (B) Time-dependent increase
in the urate transport by ABCG2. The urate transport into membrane vesicles was measured at the indicated periods with (closed) or without (open) ATP. Values are
expressed as mean ± SD. (n = 3). (C) The urate transport activities of ABCG2 in the presence of each SUA-affecting drug. Concentrations of each drug are shown
in Table 1. The urate transport into membrane vesicles was measured in the presence of each SUA-affecting drug for 10 min. Data are shown as the percentage of
vehicle control (without drugs). Values are expressed as mean ± SD (n = 3).
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FIGURE 2 | Dose-dependent inhibition of ABCG2-mediated urate transport by serum uric acid (SUA)-affecting drugs. The urate transport activities were
measured in the presence of the following drugs at the indicated concentrations for 10 min. (A) Losartan, (B) Fenofibrate, (C) Atorvastatin, (D) Cyclosporine,
(E) Furosemide, (F) Tacrolimus, (G) Rosuvastatin, (H) Benzbromarone, (I) Topiroxostat, and (J) Febuxostat. Data are shown as the percentage of vehicle control
(without drugs). Values are expressed as mean ± SD (n = 3).
presence of 100 nM of each compound, the urate transport
activities of ABCG2 were 20± 3% with febuxostat, 75± 10% with
Ko143 and 92 ± 10% with elacridar compared with the vehicle.
These results indicate that the inhibitory effect of febuxostat
against ABCG2 is stronger than those of these well-known
ABCG2 inhibitors.
Next, we estimated the fuCmax based on the general
information from pharmaceutical industries as described in
Section “Materials and Methods” (Table 2), and calculated
the ratio of fuCmax/IC50, as an indicator of the possible
in vivo clinical inhibition of ABCG2 by each drug. A high
fuCmax/IC50 value suggests that the drug has the potential to
TABLE 2 | Calculated IC50 values for ABCG2-mediated urate transport
activity and estimated fu, Cmax and fuCmax values of SUA-affecting drugs.
Drugs IC50
[µM]
fu Cmax [µM] fuCmax
[µM]
In vivo risk
factor
(fuCmax/IC50)
Losartan 35 2.0 × 10−2 1.4 2.8 × 10−2 8.1 × 10−4
Fenofibrate 5.1 1.0 × 10−2 25 2.5 × 10−1 4.8 × 10−2
Atorvastatin 4.3 4.4 × 10−2 2.2 × 10−3 9.6 × 10−5 2.2 × 10−5
Cyclosporine 3.2 1.0 × 10−1 8.1 × 10−1 8.1 × 10−2 2.5 × 10−2
Furosemide 3.2 9.0 × 10−2 2.7 2.4 × 10−1 7.7 × 10−2
Tacrolimus 3.1 1.0 × 10−2 5.4 × 10−2 5.4 × 10−4 1.7 × 10−4
Rosuvastatin 2.3 1.2 × 10−1 9.4 × 10−3 1.1 × 10−3 4.8 × 10−4
Benzbromarone 0.20 3.7 × 10−2 5.4 2.0 × 10−1 9.9 × 10−1
Topiroxostat 0.18 2.5 × 10−2 7.0 × 10−1 1.7 × 10−2 9.9 × 10−2
Febuxostat 0.027 2.2 × 10−2 4.1 9.0 × 10−2 3.4
The unbound fraction (fu), maximum concentration (Cmax) and maximum unbound
concentration in human plasma (fuCmax) values were calculated based on the
information provided by pharmaceutical industries. As an in vivo risk factor, we
determined the value of fuCmax/IC50. The large value of this score reflects the
possibility of ABCG2 inhibition by drugs in humans at clinical dose.
inhibit ABCG2 in humans. Among the 10 drugs we examined,
benzbromarone and febuxostat had a relatively high fuCmax/IC50
value (benzbromarone and febuxostat, 0.99 and 3.4, respectively).
Since febuxostat had the highest fuCmax/IC50 value and was
expected to inhibit ABCG2 in humans, we proceeded to further
analyze this drug.
Febuxostat Drastically Increased
Intestinal Absorption of Sulfasalazine in
WT Mice, But Not in Abcg2 KO Mice
Our in vitro findings strongly suggested that febuxostat would
inhibit ABCG2 in vivo. To examine this possibility, we
investigated the inhibitory effect of febuxostat on the intestinal
absorption of an ABCG2 substrate drug in WT and Abcg2
KO mice. Prior to the in vivo analyses, we confirmed that
febuxostat inhibited mouse Abcg2 in vitro in a similar manner
to human ABCG2 as described above. The IC50 value of
febuxostat against the urate transport activity of mouse Abcg2
was 35 nM (Figure 3A), which was comparable to that
of human ABCG2 (IC50, 27 nM, Table 2), indicating that
febuxostat inhibited mouse Abcg2 as strongly as it did human
ABCG2.
To examine whether febuxostat inhibited Abcg2 in vivo, we
focused on its effect on the absorption of sulfasalazine, an ABCG2
substrate, in the intestine where ABCG2 acts as a gatekeeper for
xenobiotics. It is noteworthy that the intestinal absorption of
sulfasalazine majorly depends on the ABCG2 function in both
humans and mice (Zaher et al., 2006; Yamasaki et al., 2008).
First, we addressed the time-dependent changes in the plasma
concentration of orally administered sulfasalazine in WT mice. In
WT mice pretreated with febuxostat, the plasma concentration of
sulfasalazine was significantly higher than that in control mice at
every time point (Figure 3B).
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FIGURE 3 | Inhibition of mouse Abcg2 by febuxostat in vitro and in vivo. (A) Dose-dependent inhibition of mouse Abcg2 by febuxostat in vitro. The urate
transport activities of mouse Abcg2 were measured in the presence of febuxostat at the indicated concentrations. Data are shown as the percentage of vehicle
control (without febuxostat). Values are expressed as mean ± SD (n = 3). (B) Time-dependent changes in sulfasalazine plasma concentration with the
pre-administration of febuxostat. Twenty minutes after the oral administration of febuxostat (n = 4) or vehicle (n = 7), sulfasalazine was orally administered to WT
mice. The blood samples were collected at the indicated periods, and the plasma concentrations of sulfasalazine were determined using LC/MS/MS. Values are
expressed as mean ± SEM. (C) AUC 0−120 min of sulfasalazine in WT and Abcg2 KO mice with or without pre-administration of febuxostat. Twenty minutes after the
oral administration of febuxostat (n = 4 for both WT and Abcg2 KO) or vehicle (n = 7 and 5 for WT and Abcg2 KO, respectively), sulfasalazine was orally
administered to WT and Abcg2 KO mice. The blood samples were collected at 15, 30, 60, 90, and 120 min and then the plasma concentrations of sulfasalazine
were determined using LC/MS/MS. AUC 0−120 min was determined for each group using the well-used trapezoidal rule. Values are expressed as mean ± SEM.
Statistical analyses for significant differences were performed using two-way ANOVA followed by Tukey–Kramer method; ∗p < 0.05 vs. vehicle control WT mice;
N.S., not significantly different among groups.
We then performed similar experiments using Abcg2 KO
mice and calculated the AUC of sulfasalazine. In WT mice, the
administration of febuxostat increased the AUC of sulfasalazine
(Figure 3C). On the other hand, in Abcg2 KO mice, febuxostat
did not increase the AUC of sulfasalazine. Moreover, there
was no significant difference in the AUC of sulfasalazine
among three groups; febuxostat-treated WT mice, vehicle-treated
Abcg2 KO mice and febuxostat-treated Abcg2 KO mice. These
results suggest that febuxostat enhanced the absorption of orally
administered sulfasalazine by inhibiting Abcg2 in vivo.
Febuxostat Hardly Affected
URAT1-Mediated Transport of Urate
Some of the SUA-affecting drugs we investigated hardly affected
ABCG2 function (Figure 1C), while their effects on other
urate transporters remained unclear. Therefore, we focused on
URAT1, another physiologically important urate transporter
recognized as a pharmacological target of SUA-lowering drugs,
and compared the effects of the drugs on ABCG2 and URAT1.
To evaluate the effect of SUA-affecting drugs on the urate
transport activity of URAT1, we established an in vitro assay
system for the urate transport activity with 293A cells transiently
expressing URAT1. The expression of URAT1 in the 293A cells
was confirmed by western blot analysis (Figure 4A). Then,
we measured the amount of [8-14C]-urate incorporated into
URAT1-expressing 293A cells for 0–120 s (Figure 4B). The result
showed that the urate transport activity in URAT1-expressing
cells was more than fivefold higher than that in the mock
cells, and the amount of incorporated urate increased in a
time-dependent manner. Then, we evaluated the effect of drugs
on the URAT1 activity for 20 s in subsequent investigations.
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FIGURE 4 | Inhibitory effect of serum uric acid (SUA)-affecting drugs on the urate transport activities mediated by ABCG2 and URAT1. (A) Expression
of FLAG-URAT1 on 293A cells. Whole cell lysates (30 µg) of transient FLAG-URAT1-expressing 293A cells were subjected to western blot analysis using anti-FLAG
or anti-Na+/K+-ATPase antibody. (B) Time-dependent increase of urate transport into FLAG-URAT1-expressing 293A cells. Values are expressed as mean ± SD
(n = 3). (C) Effects of each SUA-affecting drug on the urate transport activities of ABCG2 and URAT1. The urate transport activities of ABCG2 and URAT1 were
evaluated in the presence of 3 µM of each SUA-affecting drug. Data are shown as the percentage of vehicle control (without drugs). Values are expressed as
mean ± SD (n = 3). Individual data for each drug are shown in Supplementary Figure S1.
We compared the effect of each SUA-affecting drug (final
concentration 3 µM) on the urate transport activity of ABCG2
and URAT1 (Figure 4C; Supplementary Figure S1). Among the
25 SUA-affecting drugs, only benzbromarone strongly inhibited
both ABCG2 and URAT1. The urate transport activities of
ABCG2 and URAT1 in the presence of 3 µM benzbromarone
were 13 ± 2% and 12 ± 5%, respectively, compared to the
vehicle control. On the other hand, febuxostat and topiroxostat
did not affect the urate transport activity of URAT1, although
they potently inhibited ABCG2. The rest of the investigated drugs
had little effect on both ABCG2 and URAT1 at 3 µM.
DISCUSSION
In the present study, we examined the effects of 25 SUA-affecting
drugs on the transport activity of ABCG2 in an attempt to identify
a new chemical modulator of ABCG2 function from drugs on
the market. The results of the in vitro screening identified 10
drugs that had inhibitory effects on ABCG2 function while the
screening library did not contain drugs that strongly enhanced
ABCG2 function. Further analyses demonstrated that febuxostat
inhibited ABCG2 in vitro at clinical concentrations (Figure 2;
Table 2) and in vivo in the murine intestine (Figure 3). Based on
these in vitro and in vivo findings, it is possible that febuxostat
has potential to inhibit ABCG2 in humans. It is worth noting
that the inhibitory effect of febuxostat against ABCG2 was more
potent than those of two well-known ABCG2 inhibitors, Ko143
and elacridar. This means that febuxostat has advantages not only
in the safety but also in the inhibitory ability against ABCG2
as compared with those two ABCG2 inhibitors. Accordingly, in
our opinion, febuxostat would be the most promising ABCG2
inhibitor in humans.
The deliberate administration of febuxostat as an ABCG2
inhibitor could contribute to improving the pharmacokinetics
and efficacy of ABCG2 substrate drugs (Figure 5A). Subjects
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FIGURE 5 | Summary of potential effects of inhibiting ABCG2 in vivo. (A) Schematic illustration of potential precautions and putative application of febuxostat
as an ABCG2 inhibitor. (B) Schematic illustration of canceled out mechanism of benzbromarone, febuxostat and topiroxostat as SUA-lowering drugs. ALA,
5-aminolevulinic acid; Feb, febuxostat; Top, topiroxostat; Ben, benzbromarone.
with ABCG2 SNPs, which lower ABCG2 function, reportedly
exhibit higher bioavailability of ABCG2 substrates such as
sulfasalazine (Yamasaki et al., 2008) and rosuvastatin (Keskitalo
et al., 2009) than subjects with ABCG2 WT. Therefore, febuxostat
could induce a similar effect on the drug absorption in
humans. In this regard, the present study provided supportive
data demonstrating the febuxostat-dependent enhancement
of intestinal absorption of sulfasalazine in mice (Figure 3).
In pharmaceutical fields, taking advantages of inhibitory
effect of ritonavir on CYP3A4, enhanced bioavailability of
CYP3A4 substrate drugs is achieved by co-administration
of ritonavir, which is known as ritonavir-boosting (Larson
et al., 2014). Similarly, we propose here the possibility that
febuxostat has considerable potential benefits in the form of a
febuxostat-boosted therapy, which should be validated in future
clinical investigations.
Moreover, the in vivo inhibition of ABCG2 could also
be useful in cancer therapy (Figure 5A). Since ABCG2 is
one of the genes responsible for the development of MDR
in cancer cells, the inhibition of ABCG2 could enhance the
efficacy of chemotherapy, leading to an efficient accumulation of
anticancer agents. In addition, ABCG2 is involved in the eﬄux of
photosensitizers in 5-aminolevulinic acid-based photodynamic
therapy (PDT) and photodynamic diagnosis (PDD) (Ishikawa
et al., 2015; Palasuberniam et al., 2015). Considering that ABCG2
is expressed in cancer cells, febuxostat might enhance the
efficacies of PDT/PDD by accumulating photosensitizers in the
target cells.
Febuxostat-dependent impairment of ABCG2 function might
have harmful effects as a risk factor for adverse events in
combination medications (Figure 5A). For instance, while the
efficacy of rosuvastatin would be enhanced by ABCG2 inhibition
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as described above, excess administration of rosuvastatin could
induce rhabdomyolysis, a well-known severe adverse event
(Magni et al., 2015). A similar concern has been raised with
sunitinib, which could induce hand-foot skin reactions at high
doses (Mizuno et al., 2010; Massey et al., 2015). Therefore, if
febuxostat is co-administered with rosuvastatin or sunitinib and
subsequently inhibits ABCG2, the bioavailability and plasma
concentration of these drugs could be increased, resulting in
an increased risk of adverse events. Hence, the physiological
condition of the subjects administered febuxostat and ABCG2
substrate drugs should be monitored carefully. If the symptoms
of adverse events are observed, a dose reduction of the ABCG2
substrate drugs should be considered.
Indeed, febuxostat, an SUA-lowering drug, could be clinically
used with rosuvastatin and sunitinib. Rosuvastatin is a well-used
drug in patients with dyslipidemia, likely to be complicated by
hyperuricemia. Namely, there are numerous patients who are
aﬄicted with these two lifestyle-related diseases, suggesting the
possibility of simultaneous administration of rosuvastatin and
febuxostat. In the case of sunitinib, we should mention the recent
approval of febuxostat for the prevention of tumor lysis syndrome
(TLS) in Europe and Japan. TLS is an oncogenic emergency
resulting in metabolic disturbances including drastic increases
in SUA levels. Considering the risk of TLS in chemotherapy
with sunitinib (Nicholaou et al., 2007), the co-administration of
febuxostat with sunitinib would increase in the near future.
The clinical prospects of febuxostat as an ABCG2 inhibitor
should be confirmed by clinical investigations in future to
compensate the limitation in the translational implication of the
current study. Considering the diversity of substrate specificity
in ABC transporters that is responsible for the multidrug
eﬄux (Haimeur et al., 2004; Szakacs et al., 2006; Toyoda
et al., 2008; Giacomini et al., 2010), the inhibitory effect of
febuxostat on the other ABC transporters such as ABCB1
(known as P-glycoprotein) and ABCCs would be of interest. In
the case of the development of ABCB1 inhibitors, despite the
presence of a number of potential candidates, there have been
no clinically approved substances because of their intolerable
adverse effects and/or insufficient efficacy. Thus, clinical studies
for the evaluation of the combination use of febuxostat should
be carefully conducted with attention to unpredictable adverse
events and its efficacy.
Focusing on urate kinetics, our results suggest that existing
SUA-lowering drugs should have a room for improvement in
efficacy. To develop more effective SUA-lowering drugs, the
biological effect of the candidates should be carefully assessed
not only on their primary molecular targets but also on
other urate transporters or metabolic enzymes. Approved SUA-
lowering drugs function as inhibitors of either xanthine oxidase
(XO), a urate production enzyme, or URAT1. Allopurinol,
the oldest XO inhibitor, has been used for patients with
hyperuricemia over the last half-century (Watts et al., 1965),
even though this drug has a risk of severe adverse events such
as aplastic anemia (Arellano and Sacristan, 1993). The safety
analyses of XO inhibitors in previous studies pointed out that
both febuxostat and topiroxostat are superior to allopurinol
(Matsumoto et al., 2011; Takano et al., 2005). However, the
present study revealed the possibility that febuxostat and
topiroxostat could inhibit ABCG2, resulting in the partial
cancelation of their efficacy as a SUA-lowering drug (Figure 5B).
Therefore, the SUA-lowering effects of these drugs might be
weaker than expected because of their inhibition of ABCG2-
mediated urate excretion. A similar inhibition pattern is also the
case with benzbromarone, a URAT1 inhibitor (Figure 5B). Since
allopurinol, febuxostat, topiroxostat and benzbromarone are the
major SUA-lowering drugs presently known, the development
of SUA-lowering drugs that do not inhibit ABCG2 would be
the next strategy for developing a more effective hyperuricemia
therapy.
CONCLUSION
We demonstrated that febuxostat potently inhibited ABCG2
both in vitro and in vivo, suggesting that it could be the first
clinical and safe ABCG2 inhibitor in humans. The possible
drug–drug interaction between febuxostat and ABCG2 substrate
drugs would have both beneficial and harmful effects. Our
successful demonstration is an example of the promising
beneficial effects, which provided the proof of concept for the
potential of febuxostat-boosting. To ensure the safe clinical
application of febuxostat, further investigations in humans would
be important.
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